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Current management practices for hyponatremia (HN) are
incompletely understood. The HN Registry has recorded
diagnostic measures, utilization, efficacy, and outcomes of
therapy for eu- or hypervolemic HN. To better understand
current practices, we analyzed data from 3087 adjudicated
adult patients in the registry with serum sodium
concentration of 130mEq/l or less from 225 sites in the
United States and European Union. Common initial
monotherapy treatments were fluid restriction (35%),
administration of isotonic (15%) or hypertonic saline (2%),
and tolvaptan (5%); 17% received no active agent. Median
(interquartile range) mEq/l serum sodium increases during
the first day were as follows: no treatment, 1.0 (0.0–4.0); fluid
restriction, 2.0 (0.0–4.0); isotonic saline, 3.0 (0.0–5.0);
hypertonic saline, 5.0 (1.0–9.0); and tolvaptan, 4.0 (2.0–9.0).
Adjusting for initial serum sodium concentration with logistic
regression, the relative likelihoods for correction by 5mEq/l
or more (referent, fluid restriction) were 1.60 for hypertonic
saline and 2.55 for tolvaptan. At discharge, serum sodium
concentration was under 135mEq/l in 78% of patients and
130mEq/l or less in 49%. Overly rapid correction occurred in
7.9%. Thus, initial HN treatment often uses maneuvers of
limited efficacy. Despite an association with poor outcomes
and availability of effective therapy, most patients with HN
are discharged from hospital still hyponatremic. Studies to
assess short- and long-term benefits of correction of HN with
effective therapies are needed.
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Hyponatremia (HN), defined as a serum sodium concentra-
tion ([Naþ ]) below the lower limit of normal, is the most
common electrolyte disorder in hospitalized patients, with a
prevalence as high as 30–42%.1,2 HN is independently asso-
ciated with mortality in congestive heart failure (CHF), cirrhosis,
and hospitalized patients in general3–7 and with increased
hospital costs and readmission rates.8,9 Chronic HN has been
linked to impaired gait and balance, increased falls and
fracture rates, and osteoporosis.10–13 However, a causal role of
HN for these associations is largely unproven.14
Correction of severe HN of sudden onset can be genuinely
lifesaving,15, and treatment of chronic HN associated with
neurological symptoms is undeniably beneficial. Despite the
widespread clinical impression that correction of less severe
chronic HN is also worthwhile, evidence-based data demon-
strating clinical benefit are limited.10,16–18
Hypovolemic HN responds readily to volume repletion.
Until recently, treatment of hypervolemic HN has been
limited to fluid restriction (FR) and correction of the
underlying disorder. Treatment modalities for euvolemic
HN have included FR, hypertonic saline (HS), loop diuretics,
demeclocycline, and urea. With the approval of the
vasopressin-receptor antagonists conivaptan and tolvaptan,
more targeted treatment for euvolemic and hypervolemic HN
became available. It remains uncertain how treatment
options are employed, and how correction magnitude and
incidence of adverse outcomes are affected by the type of
therapy. With this background, the multinational HN
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Registry was initiated to assess the current state of treat-
ment of euvolemic and hypervolemic HN in diverse,
real-world hospital settings. Its specific purpose was to
determine which diagnostic and treatment modalities
are currently employed, how effective they are, and how
rapidly and reliably they result in an increase in [Naþ ]. An
additional goal was to determine which treatments posed the
greatest risk of overly rapid correction and osmotic
demyelination.19
RESULTS
Characteristics of study population
A total of 5028 patients were entered (Figure 1) between
September 2010 and February 2013. One or more criteria
requiring adjudication were met by 2705 patients (54% of
those entered), and 1941 of those (72%) failed adjudication.
The 764 patients (28%) retained after adjudication and the
2323 (46% of those entered) not requiring adjudication
comprise the 3087 individuals of the per-protocol data set.
A sensitivity analysis performed with and without the 951
potentially hypovolemic patients excluded because of thiazide
use or evidence of volume depletion showed no signi-
ficant differences in rates of [Naþ ] change or achievement
of [Naþ ] correction benchmarks. The syndrome of
inappropriate antidiuretic hormone (SIADH), CHF, and
cirrhosis data sets include patients in whom these diagnoses
were made by treating physicians.
Patient demographics and baseline characteristics are
shown in Table 1. Patients with cirrhosis were younger and
more likely to be male compared with patients with SIADH
or CHF. A prior episode of HN was known to have occurred
in 909 patients (29%) and was most likely in patients with
cirrhosis and least likely in those with SIADH. Most patients
(71%) were under the care of a generalist rather than an
internal medicine subspecialist.
Diagnosis
In the 1524 patients with SIADH, serum osmolality was
measured in 66%, urine osmolality in 68%, and urine [Naþ ]
in 63%; all three tests were performed in 47%, and none in
11%. Cortisol was measured in 33% of patients and thyroid-
stimulating hormone in 64%. All five of these measurements
were made in 21% of patients.
Treatment selection
As shown in Table 2, 17% of patients received no active HN
therapy. Utilization varied with [Naþ ]. Only 3% of patients
with severe HN received no therapy compared with 13% with
Screened
n = 5 306
Entered
n =5 028 (95%)
Failed screening
n =278 (5%)
Adjudication required
n =2 705 (54%)
Adjudication not required
n =2 323 (46%)
Adjudication criteria met
n =764 (28%)
Receiving a thiazide, n =521 (27%)
Single [Na+] value ≤130 mEq/l and no active therapy, n =672 (35%)
Suspected volume depletion, n =430 (22%)
Hyperglycemia, n =131 (7%)
Renal replacement therapy, n =79 (4%)
HN etiology mismatched or undocumented, n =106 (5%)
Insufficient data, n =2 (<1%)
Per-protocol population
n =3 087 (61%)
Hypervolemic
n =1 490 (48%)
CHF
n =762 (51%)
Cirrhosis
n =630 (42%)
Other
n =98 (7%)
SIADH
n =1 524 (95%)
Other
n =73 (5%)
Euvolemic
n =1 597 (52%)
Dropped during adjudication
n = 1 941 (72%)
Figure 1 | Consort diagram showing patient flow. The 3087 patients in bottom row constitute the per-protocol group. All analyses are based
on this group. Note: patients reporting multiple comorbidities were counted in the ‘‘Other’’ group. See Materials and Methods section and
Supplementary Table S4 online for description of the adjudication process. CHF, congestive heart failure; HN, hyponatremia; [Naþ ], sodium
concentration; SIADH, syndrome of inappropriate antidiuretic hormone secretion.
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moderate HN and 25% with mild HN (Po0.001). Stopping a
medication that may induce SIADH could also be considered
an active treatment; of the 509 patients who received no
active HN therapy, 265 (52%) were receiving a potentially
HN-inducing medication (see Supplementary Table S1 online
for list), which was discontinued in 29 (11%).
The therapies utilized, according to underlying diagnosis
or severity of HN, are shown in Figures 2 and 3. Overall,
55% of patients were treated with FR or isotonic saline
(NS) or both. Treatments more likely to result in an
increase in [Naþ ]—HS or tolvaptan—were used in 7% of
patients.
FR alone was selected most frequently. NS alone or with
FR was used significantly more often in patients with SIADH
(30%) than with CHF (7%) or cirrhosis (10%). Patients with
lower baseline [Naþ ] were more likely to receive HS.
Treatment efficacy and outcomes
When used as a monotherapy, FR was least effective, although
more rigorous FR (p1000ml/day) resulted in a more rapid
Table 1 | Baseline demographic characteristics by comorbidity
All Patientsa (N¼ 3087) SIADH (n¼ 1524) CHF (n¼ 762) Cirrhosis (n¼ 630)
Age distribution, n (%)b
p50 years 479 (16) 186 (12) 76 (10) 190 (30)
51–64 years 937 (30) 373 (25) 164 (22) 339 (54)
65–74 years 587 (19) 339 (22) 127 (17) 81 (13)
X75 years 1084 (35) 626 (41) 395 (52) 20 (3)
Men, n (%)c 1558 (51) 695 (46) 352 (46) 419 (67)
Race distribution: US only, n (%)b
White 1927 (74) 770 (75) 575 (76) 455 (72)
African American 309 (12) 108 (10) 123 (16) 58 (9)
Asian 57 (2) 29 (3) 10 (1) 13 (2)
Other 154 (6) 61 (6) 30 (4) 53 (9)
Unknown 149 (6) 66 (6) 24 (3) 51 (8)
Median initial [Naþ ] (IQR), mEq/ld 125.0 (120.0–128.0) 124.0 (119.0–127.0) 126.0 (122.0–129.0) 125.0 (121.0–128.0)
Median initial BUN (IQR), mg/dlb 15.83 (10.0–25.0) 12.0 (9.0–17.0) 22.0 (14.0–36.0) 20.0 (13.0–33.0)
Median initial creatinine (IQR), mg/dle 0.85 (0.6–1.2) 0.70 (0.6–0.9) 1.10 (0.8–1.6) 1.03 (0.8–1.5)
Initial BUN:creatinine ratio (IQR),b 17.8 (13.3–23.4) 16.7 (12.2–21.9) 20.0 (15.2–26.0) 18.2 (14.1–24.0)
Median initial blood glucose (IQR), mg/dl 112 (97.0–134.0) 110 (96.0–130.0) 116 (101.0–141.0) 109 (95.0–133.0)
Prior HN, n (%)b,f
Yes 909 (29) 407 (27) 209 (27) 240 (38)
No 1176 (38) 687 (45) 253 (33) 178 (28)
Unknown 1001 (32) 430 (28) 299 (39) 212 (34)
HN at admission, n (%)g
Yes 2532 (82) 1252 (82) 605 (79) 549 (87)
No 531 (17) 253 (17) 153 (20) 81 (13)
Unknown 24 (1) 19 (1) 4 (1) 0 (0)
Primary physician specialty, n (%)
Nephrologist 104 (3) 82 (5) 10 (1) 8 (1)
Endocrinologist 108 (4) 106 (7) 2 (o1) 0
Cardiologist 321 (10) 49 (3) 247 (32) 7 (1)
Hepatologist 260 (8) 3 (o1) 4 (1) 246 (39)
Oncologist 111 (4) 92 (6) 5 (1) 11 (2)
Generalist 1844 (60) 944 (62) 466 (61) 315 (50)
Other 338 (11) 247 (16) 28 (4) 43 (7)
HN subspecialist consulted, n (%)h,i
No 1989 (64) 839 (55) 530 (70) 501 (80)
Yes 1096 (36) 683 (45) 232 (30) 129 (21)
Abbreviations: BUN, blood urea nitrogen; CHF, congestive heart failure; HN, hyponatremia; [Naþ ], sodium concentration; IQR, interquartile range; SIADH, syndrome of
inappropriate antidiuretic hormone secretion.
Median (IQR) B-type natriuretic peptide value in the CHF patients was 733.5 pg/ml (1465.0), n¼ 410.
aIncludes 171 either patients without a diagnosis of SIADH, cirrhosis, or CHF or with multiple comorbidities.
bSIADH versus CHF and cirrhosis, and CHF vs. cirrhosis: Po0.001.
cSIADH versus CHF: P¼ 0.79; and SIADH and CHF versus cirrhosis: Po0.001.
dSIADH versus CHF and cirrhosis: Po0.001; CHF versus cirrhosis: P¼ 0.01.
eSIADH versus CHF and cirrhosis: Po0.001; and CHF versus cirrhosis: P¼ 0.005.
fHN during previous hospital admission in prior 12 months.
gData missing for 24 patients in all, 19 in SIADH and 4 in CHF populations; SIADH versus CHF: P¼ 0.04; SIADH versus cirrhosis: P¼ 0.001; and CHF versus cirrhosis: Po0.001.
hSIADH versus CHF and cirrhosis: Po0.001; and CHF versus cirrhosis: P¼ 0.01.
iHN specialist defined as nephrologist or endocrinologist.
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[Naþ ] increase compared with a lesser degree of FR
(Table 3). Addition of FR to the other monotherapies had
a small effect, if any. Median (interquartile range) rate of
change with NS alone was 2.0 (0.3–4.0) versus 2.4 (1.0–5.0)
mEq/l/day with addition of FR (P¼ 0.004), but rate of
change, correction rate, or frequency of overly rapid
correction did not change significantly with addition of FR
to any other monotherapy. Examined categorically (Figure 4),
correction of [Naþ ], defined de minimus as a [Naþ ] increase
42mEq/l, was more likely and lack of correction, defined as
a final [Naþ ] within 2mEq/l of the starting [Naþ ], less likely
with HS or tolvaptan than with FR or NS. [Naþ ] was also
less likely to decrease by 42mEq/l in patients who received
HS or tolvaptan than in patients who received FR or NS
as monotherapy. For decrease 42mEq/l: FR versus HS,
P¼ 0.03; FR versus tolvaptan, Po0.01; NS versus HS,
P¼ 0.04; NS versus tolvaptan, P¼ 0.01.
Overall success in reaching various correction benchmarks
is shown in Table 4 for initial monotherapy episodes. Overall,
22% of patients reached a normal [Naþ ] X135mEq/l. Rate
of correction by X5mEq/l with HS was similar to that of
tolvaptan in the unadjusted analysis. However, the utilization
of various treatments varied with baseline [Naþ ] (Figure 3).
When achievement of [Naþ ] change benchmarks was
adjusted for starting [Naþ ] using logistic regression
(Table 4), only tolvaptan produced a consistently higher rate
of success in reaching all three benchmarks. Compared with
FR, NS was worse in two of three benchmarks. HS was more
likely to result in a [Naþ ] X5mEq/l. When the [Naþ ]
interaction was examined categorically rather than continu-
ously (Supplementary Table S2 online), the relative likelihood
of reaching any of the three benchmarks for HS compared
with FR was not different from unity for mild, moderate, or
severe HN. In a similar categorical analysis comparing
tolvaptan with FR, the relative likelihood of correction to
[Naþ ]4130mEq/l was 3.131 (1.7324–5.658) with mild HN,
2.106 (1.435–3.092) with moderate HN, and 1.410
(1.007–1.974) with severe HN. The relative likelihood of
correction 45mEq/l was 2.202 (1.446–3.353) with mild HN
and 3.533 (1.772–7.044) for moderate HN. The relative
likelihood of correction to [Naþ ] 4135mEq/l was 1.817
(1.340–2.464) for mild HN and 1.200 (1.021–1.409) for
moderate HN. The relative likelihoods for other benchmarks
or starting [Naþ ] values did not differ from unity. In some
categories, the number of cases was quite small.
As FR was the most frequently prescribed initial therapy,
we separately analyzed the course of patients after FR. A total
of 922 patients (30%) with a baseline [Naþ ] o130mEq/l
were treated with FR initially (Figure 5). The majority did not
correct [Naþ ] by an increment X5mEq/l and the majority
of those patients received no additional treatment.
Overly rapid correction of [Naþ ] occurred in 7.9% of
patients overall (Table 5) and was most likely in patients with
SIADH (10.7%) and least likely with cirrhosis (3.6%;
Po0.001, SIADH vs. cirrhosis). Of patients who received
no active therapy, 1.4% experienced overly rapid correction.
Compared with no therapy, the relative risk (95% confidence
interval) for overly rapid correction was 1.6 (0.70–3.57) for
FR, 2.35 (0.97–5.65) for NS, 12.01 (5.14–28.04) for HS, and
8.57 (3.84–19.12) for tolvaptan. Overall, 17.1% of patients
receiving HS and 10.8% of patients receiving tolvaptan
monotherapy at any time (P¼ 0.08, HS vs. tolvaptan) experi-
enced overly rapid correction, similar to the results for initial
treatment responses (Table 3). Included among the overly
rapid correction episodes that occurred with active therapy
are one episode with HS and two with tolvaptan in patients
Table 2 | Treatment utilization according to diagnosis or severity of HN
Number of therapy episodes or unique therapies employed
No therapy, n (%) 1 Episode, n (%) X2 Episodes, n (%) Median therapy episodes/patient (IQR), n
All patients (n¼ 3087) 509 (17) 1148 (37) 1430 (46) 2.0 (1.0–3.0)
Comorbidity
SIADH (n¼ 1524) 170 (11) 451 (30) 903 (59) 2.0 (1.0–3.0)
CHF (n¼ 762) 176 (23) 325 (43) 261 (34) 1.0 (1.0–3.0)
Cirrhosis (n¼ 630) 125 (20) 298 (47) 207 (33) 1.0 (1.0–2.0)
Starting [Naþ ], mEq/l
o120mEq/l (n¼ 653) 22 (3) 207 (32) 424 (65) 2.0 (1.0–3.0)
120–125mEq/l (n¼ 1048) 139 (13) 379 (36) 530 (51) 2.0 (1.0–3.0)
4125–130mEq/l (n¼ 1386) 348 (25) 562 (41) 476 (34) 1.0 (1.0–2.0)
Abbreviations: CHF, congestive heart failure; HN, hyponatremia; IQR, interquartile range; [Naþ ], sodium concentration; SIADH, syndrome of inappropriate antidiuretic
hormone secretion.
Episode of therapy refers to an interval during which a treatment or combination of treatments was given specifically for HN without interruption. For purposes of this
analysis, treatment of CHF patients for congestion was not considered a specific treatment of HN as any patient with CHF would have been so treated.
No HN therapy: Po0.001, SIADH versus CHF and cirrhosis; P¼ 0.14, CHF versus cirrhosis; Po0.001, mild versus moderate and severe, and moderate versus severe HN.
One episode: Po0.001, SIADH versus CHF and cirrhosis; P¼ 0.09, CHF versus cirrhosis; P¼ 0.08, mild versus severe HN; P¼ 0.03, mild versus moderate HN; P¼ 0.06,
moderate versus severe HN.
X2 episodes: Po0.001, SIADH versus CHF and cirrhosis; P¼ 0.58, CHF versus cirrhosis; Po0.001, mild versus moderate and severe, and moderate versus severe HN.
Therapy episode/patient: Po0.001, SIADH versus CHF and cirrhosis; P¼ 0.29, CHF versus cirrhosis; Po0.001, mild versus moderate and severe, and moderate versus
severe HN.
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who were also receiving variable doses of desmopressin to
treat diabetes insipidus post parasellar surgery. A further six
episodes with tolvaptan occurred after suprasellar or pituitary
procedures alone. In total, six of these postoperative cases
occurred at a single center. The group with the lowest starting
[Naþ ] was at greatest risk for overly rapid correction: 3.6%
for mild HN (referent), 5.0% (relative risk 1.39 (95% confi-
dence interval 0.94–2.06)) for moderate HN, and 19% (5.34
(3.86–7.40)) for severe HN. No cases of the osmotic demye-
lination syndrome were documented in the HN Registry.
A generalist or specialist other than an HN specialist
(i.e., nephrologist or endocrinologist) served as attending
physician for 2775 patients. Of this subset, 619 of 1035
patients (60%) for whom a HN specialist was consulted
versus 767 of 1720 (45%) for whom no HN specialist
was consulted were discharged with [Naþ ] 4130mEq/l
(Po0.001).
The mean length of stay was 10.3±9.2 days for the group
as a whole and did not vary by category of [Naþ ], diagnosis,
or treatment employed. Comparisons of median length of
stay for patients on any monotherapy tended to be longer
for the group of patients not discharged until [Naþ ] was
4130mEq/l (Supplementary Figure S1 online). Correction
of HN to [Naþ ] 4130mEq/l was not associated with
survival; 7% of all patients who corrected versus 8% who did
not correct (P¼ 0.58) died or were discharged to hospice
care.
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Figure 2 | Initial therapy of hyponatremia. Bars show percentages of patients receiving specified therapy. Lines show cumulative proportions
of patients receiving therapies shown. CHF, congestive heart failure; FR, fluid restriction; HN untreated, no specific treatment targeted at
hyponatremia at any time during hospitalization; HS, hypertonic saline; NS, isotonic saline; SIADH, syndrome of inappropriate antidiuretic
hormone; TO, tolvaptan. aTherapies given to X1% of patients; b7.6.0%, c9.3%, d5.2%, and e3.1% of patients received other unique therapies.
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DISCUSSION
The HN Registry is the largest observational HN study to
date and unique in its examination of the diagnosis,
treatment, and outcome of HN in diverse hospital settings
in the US and EU. Several important and novel findings have
emerged from analysis of the results.
Determining the cause of HN is the first step in evaluating
patients with HN and is crucial to guiding correct manage-
ment.20–22 Specific testing is generally not required with
hypervolemic HN, but proper diagnosis of SIADH requires
measurement of urine and plasma osmolality and urine
[Naþ ] at a minimum.20,22,23 Only 47% of patients with
SIADH as identified by treating physicians had all three
cardinal tests performed, and 11% underwent none. The full
diagnostic criteria include normal thyroid and adrenal func-
tion,24 but only 21% of identified SIADH patients underwent
cortisol and thyroid hormone determinations, along with
the required electrolyte and osmolality measurements. These
results confirm previous findings of smaller single-center
studies.25,26 The failure to make a precise diagnosis could
have important sequelae.
HN has been associated with poor outcomes and higher
hospital costs.3,4,6–8,10 Correction of HN in selected patients
with CHF is associated with improved survival,16,17 and
improved long-term survival following correction of HN in
patients in general has been observed.27 Experimentally, HN
has been shown to have direct effects on cardiac fibrosis and
myocyte function.28,29 HN at hospital discharge is associated
with risk of readmission.17 Despite the suggestion from these
studies that HN is deleterious, the results of the HN Registry
strongly infer that clinicians are not presently convinced that
correction of HN is worthwhile. Fully 17% of patients
received no specific treatment for HN beyond discontinuing
potentially HN-inducing medicines or treating conditions
like pain, pneumonia, or CHF that may lead to HN. Further-
more, more than three quarters of patients were discharged
still hyponatremic. Even using a less stringent criterion,
only half of the patients overall reached a [Naþ ]4130mEq/l
by the time of discharge. Among the 56% of patients
treated initially with FR alone who failed to increase [Naþ ]
by 45mEq/l, the treating physicians selected a second
treatment in only 44%.
In the HN Registry, the choice of treatment, like the choice
of diagnostic studies, was left up to the treating physicians.
FR was used most often as the initial therapy irrespective of
the etiology of the HN. This therapy is unlikely to result in
an increase in [Naþ ] if urine osmolality is high (i.e.,
4500mOsm/kg H2O), or the ratio of urine-to-plasma
electrolyte concentrations is 41.0, but these parameters
were rarely evaluated.20,21,30,31 Among patients in the HN
Registry, over the first day of its use as monotherapy, FR led
only to a very modest rise in [Naþ ], 2.0mEq/l. Characteri-
zation of the categorical responses of individual patients
showed that 8% treated initially with FR or NS actually
Table 3 | Response to therapy for initial monotherapy episodes
Overly rapid correction, n (%)
Treatment Patients, n
Median baseline
[Naþ ] (IQR), mEq/l
Median rate of
[Naþ ] change (IQR),
mEq/l/daya
Median first day
change (IQR),
mEq/l/dayb
Mean duration
of Rx (IQR), daysc 24 or 48hd 24 Hourse
No treatment 507 127.0 (125.0–129.0) 0.4 (0.0–1.0) 1.0 (0.0–4.0) 6.0 (4.0–9.0) 7 (1.4) 7 (1.4)
Fluid
restriction 992 125.0 (121.0–127.0) 1.0 (0.0–2.0) 2.0 (0.0–4.0) 4.0 (2.0–7.0) 15 (1.4) 13 (1.2)
p1000ml 399 123.0 (120.0–126.0) 1.2 (0.3–2.5) 2.0 (0.0–4.0) 3.0 (1.0–5.0) 4 (1.0) 4 (1.0)
41000ml 529 126.0 (122.0–128.0) 0.7 (0.0–2.0) 2.0 (0.0–4.0) 4.0 (2.0–7.0) 7 (1.3) 6 (1.1)
Normal saline 428 123.0 (119.0–127.0) 2.0 (0.3–4.0) 3.0 (0.0–5.0) 1.0 (1.0–2.0) 13 (2.9) 10 (2.2)
Hypertonic saline 72 118.5 (114.5–124.0) 3.1 (1.7–7.8) 5.0 (1.0–9.0) 2.0 (1.0–3.0) 12 (16.0) 11 (14.7)
Tolvaptan 131 124.0 (120.0–128.0) 3.3 (1.4–7.0) 4.0 (2.0–9.0) 2.0 (1.0–4.0) 16 (11.6) 12 (8.7)
Abbreviations: HN, hyponatremia; [Naþ ], sodium concentration; IQR, interquartile range; Rx, treatment.
Table comprises results of the first treatment given specifically to treat HN if only a single modality was used.
aCalculated as total increment in [Naþ ] during the period of treatment utilization/no. of treatment days (interval of HN used for no treatment group).
bCalculated incremental change during the first 24±12h window. The actual interval for any individual patient ranged from 12 to 36h, depending on the timing of the
reported laboratory values.
cDuration of HN therapy is defined as the last day of initial HN therapy episode minus the start of the initial HN therapy episodeþ 1.
dDefined as increment in [Naþ ] 412mEq/l in 24h or 18mEq/l in 48h.
eDefined as increment in [Naþ ] 412mEq/l in 24h.
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Figure 4 | Change in serum sodium concentration from baseline
by initial monotherapy. FR, fluid restriction; HN, hyponatremia; NS,
isotonic saline.
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experienced further decreases in [Naþ ] exceeding 2 mEq/l,
indicating that relying on these treatments alone can be
detrimental. HS and tolvaptan worked more consistently
(Figure 4) and significantly faster compared with FR
(Table 3). These agents also had very low rates of decreases
in [Naþ ] (Figure 4). When examined in the patients as a
whole, HS and tolvaptan had similar efficacy in increasing
[Naþ ] byX5mEq/l and were each more effective compared
with FR or NS. Baseline [Naþ ] varied significantly between
treatments, in some cases with little overlap (Table 3).
Achievement of correction benchmarks was high with no
therapy (Table 4), likely because of confounding by indica-
tion; clinicians probably added specific treatment for patients
whose [Naþ ] did not rise spontaneously concomitant with
resolution of the precipitant for HN. Indeed, detailed review
of response according to categorical baseline [Naþ ] (data not
shown) demonstrated that the majority of such patients
underwent withdrawal of an agent that would interfere with
water excretion or underwent treatment for congestion in
CHF, events that would not be captured as specific therapy
for HN in the computerized analysis. After adjustment for
baseline [Naþ ] using logistic regression, tolvaptan was
consistently better compared with FR in achieving all of the
prespecified [Naþ ] correction benchmarks, and HS was
more often associated with a [Naþ ] increment X5mEq/l.
This is consistent with clinical practice in which HS is used to
Table 4 | Achievement of correction benchmarks
[Naþ ] 4130mEq/l D[Naþ ] X5mEq/l [Naþ ] 4135mEq/l
By diagnosis
Diagnosis, n (%)a
All (N¼ 2948) 1494 (51) 1790 (61) 635 (22)
SIADH (n¼ 1422) 809 (57) 981 (69) 361 (25)
CHF (n¼ 742) 357 (48) 395 (53) 139 (19)
Cirrhosis (n¼ 618) 239 (39) 316 (51) 100 (16)
By initial monotherapy episode, unadjusted for baseline sodium concentration
Initial treatment, n (%)b
No treatment (n¼ 507) 210 (41) 195 (39) 93 (18)
Fluid restriction (n¼ 922) 269 (29) 402 (44) 93 (10)
p1000ml (n¼ 386) 93 (24) 180 (47) 31 (8)
41000ml (n¼ 474) 137 (29) 185 (39) 46 (10)
Normal saline (n¼ 397) 66 (17) 162 (41) 17 (4)
Hypertonic saline (n¼ 71) 18 (25) 46 (65) 7 (10)
Tolvaptan (n¼ 122) 80 (66) 95 (78) 41 (34)
By initial monotherapy episode, baseline sodium concentration p120
Initial treatment, n (%)b
No treatment (n¼ 22) 12 (55) 21 (95) 6 (27)
Fluid restriction (n¼ 189) 42 (22) 122 (65) 16 (8)
Normal saline (n¼ 116) 6 (5) 78 (67) 3 (3)
Hypertonic saline (n¼ 37) 5 (14) 29 (78) 1 (3)
Tolvaptan (n¼ 29) 13 (45) 24 (83) 6 (21)
By initial monotherapy episode, baseline sodium concentration 120–125
Initial treatment, n (%)b
No treatment (n¼ 138) 47 (34) 81 (59) 25 (18)
Fluid restriction (n¼ 382) 91 (24) 181 (47) 31 (8)
Normal saline (n¼ 170) 20 (12) 63 (37) 6 (4)
Hypertonic saline (n¼ 25) 9 (36) 14 (56) 4 (16)
Tolvaptan (n¼ 47) 30 (64) 40 (85) 11 (23)
By initial monotherapy episode, baseline sodium concentration 4125–130
Initial treatment, n (%)b
No treatment (n¼ 347) 151 (44) 93 (27) 62 (18)
Fluid restriction (n¼ 351) 136 (39) 99 (28) 46 (13)
Normal saline (n¼ 111) 40 (36) 21 (19) 8 (7)
Hypertonic saline (n¼ 9) 4 (44) 3 (33) 2 (22)
Tolvaptan (n¼ 46) 37 (80) 31 (67) 24 (52)
By initial monotherapy episode, relative likelihood of correction, referent, fluid restrictionc
Normal saline 0.849 (0.800–0.902) 0.953 (0.863–1.052) 0.939 (0.912–0.968)
Hypertonic saline 0.949 (0.823–1.093) 1.602 (1.162–2.207) 0.997 (0.921–1.080)
Tolvaptan 2.057 (1.605–2.637) 2.548 (1.818–3.572) 1.354 (1.191–1.539)
Abbreviations: CHF, congestive heart failure; [Naþ ], sodium concentration; SIADH, syndrome of inappropriate antidiuretic hormone secretion.
aAchievement of correction benchmark determined at discharge for diagnoses.
bAchievement of correction benchmark determined at the end of initial therapy episode.
cLogistic regression to control for baseline [Naþ ], relative likelihood (95% confidence interval).
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effect an initial correction, followed by other modalities to
raise [Naþ ] further.
The rate of [Naþ ] rise with tolvaptan was more rapid than
reported in clinical trials.18,32 With greater efficacy came
greater risk. A [Naþ ] increase 412mEq/l per 24 h or
418mEq/l per 48 h, predisposing patients to the develop-
ment of osmotic demyelination syndrome, was observed
more often in patients receiving HS or tolvaptan compared
with receiving other treatments. Pituitary surgery, a situation
where SIADH may be transient and resolve suddenly, as well
as concomitant use of desmopressin for diabetes insipidus
appear to pose a particular risk for overly rapid correction
when active therapies are used as well. Although well
described with HS, only one case of osmotic demyelination
syndrome with the use of a vasopressin-receptor antagonist
as monotherapy to correct HN has been reported to date.20,33
No cases of osmotic demyelination syndrome were observed
in the 5028 patients in the HN Registry.
The HN Registry has a number of limitations, most of
which derive from its observational design.16 Patients with
hypovolemic HN were excluded, as were those with hyper-
volemic HN in the EU cohort. A large number of patients
were excluded at the time of adjudication. Sensitivity analysis
showed no difference in the major outcomes when patients
with suspected hypovolemia were restored to the analysis. We
believe that the exclusion of these patients represents a
conservative approach. Ascertainment varied from center to
center; enrollment of consecutive cases was not required.
Consequently, the study provides no information about
relative prevalence of different etiologies of HN.34 Accurate
determination of clinical volume status is difficult under the
best of circumstances. The selection of diagnostic studies and
treatments was left up to the clinicians responsible for
patients, and the study relied on treating clinicians to make a
diagnosis. Neither a fluid challenge nor a urine sodium deter-
mination was required as an entry criterion for putatively
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Figure 5 | Outcomes and the use of second therapies in patients with baseline serum sodium concentrations o130mEq/l initially
treated with fluid restriction alone. The decision to initiate a second treatment or not and the selection of any such treatments were made
by the patients’ treating physicians without input from the investigators. All serum sodium concentration [Naþ ] values are median (IQR) in
mEq/l. HS, hypertonic saline; NS, isotonic saline; TO, tolvaptan. aPretreatment value; bsuccess defined as proportion of patients with [Naþ ]
increase by 5 mEq/l or more from baseline.
Table 5 | Rate of overly rapid correction of [Naþ ] during any
24- or 48-hour period of therapy
Initial Rx,
n/N (%)a
Any monotherapy,
n/N (%)b
Any use,
n/N (%)c
All 58/2033 (2.9) 119/2399 (5.0) 203/2578 (7.9)
By Rx
No Rx 7/509 (1.4) NA NA
Fluid restriction 15/1084 (1.4) 43/1614 (2.7) 106/1960 (5.4)
Isotonic saline 13/456 (2.9) 19/564 (3.4) 57/1150 (5.0)
Hypertonic saline 12/75 (16.0) 20/117 (17.1) 57/353 (16.1)
Tolvaptan 16/138 (11.6) 34/314 (10.8) 68/582 (11.7)
Abbreviations: NA, not applicable; [Naþ ], sodium concentration; Rx, treatment.
Overly rapid correction is defined as [Naþ ] 412meq/l in any 12h period or
418mEq/l in any 48h period.
aInitial therapy refers to first treatment modality selected for hyponatremia. Only
episodes during which a patient received only a single modality (or no treatment)
during that initial interval are included.
bMonotherapy includes any interval, initial or subsequent, during which only the
single listed treatment was received.
cAny use includes any therapy period during which specified treatment was
received irrespective of whether another treatment was also received.
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euvolemic patients. This limited our ability to exclude hypo-
volemia and independently confirm the presence of SIADH
with precision. Because the study’s intent was to capture
‘real-world’ practice, this limitation did not detract from
observing how clinician-diagnosed SIADH is treated. Indeed,
a principal conclusion is that diagnostic rigor in the case of
SIADH is severely lacking, even in a study situation where
some treating physicians were aware that their diagnostic
choices were being observed. Some therapies were used too
infrequently to assess. For example, urea, a treatment shown
to be effective in SIADH,35 and recommended in recent EU
guidelines,22 was used in only 10 patients. Because of the
large number of combinations used at low frequency, analysis
focused on monotherapy and initial therapy episodes. The
study did not specify, much less randomize, treatment choices.
We were unable to determine the rationale for choosing a
particular treatment. In particular, we could not determine
how often NS was used initially in a diagnostic trial to
exclude volume depletion in patients suspected of SIADH, a
reasonable strategy for its use.20 Choice of treatments was
likely confounded by indication, and the study cannot
accurately assess whether any particular treatment shortened
hospital stay. We were not able to fully assess how maneuvers
such as discontinuation of a HN-inducing medication or
treatment of CHF affected [Naþ ] changes or the decision to
add another treatment maneuver. As a result, even the limited
comparisons showing superiority or inferiority of particular
treatments that were feasible must be interpreted with much
circumspection.
In summary, despite the high prevalence of HN,1,2 and
published guidance on its diagnosis and treatment,20–22
numerous shortcomings in current HN management are
evident. HN in general and SIADH in particular are often
diagnosed without attention to accepted diagnostic criteria.
Strikingly, many patients receive no specific treatment for HN.
FR was predictably the most frequent initial therapy but was
ineffective in more than half of the cases. When unsuccessful, FR
was often not followed with an additional therapy. Despite the
availability of active therapies to correct [Naþ ], HS, and
vasopressin-receptor antagonists, clinicians typically discharge
patients with unresolved HN. From this study, we can conclude
that educational efforts should focus on how to diagnose
SIADH with rigor, on the lack of efficacy of FR alone and the
potential for [Naþ ] to fall with FR alone, on the use of active
treatments to raise [Naþ ] urgently when needed, and on
increasing the awareness of situations where overly rapid
correction is likely. One such circumstance highlighted in the
present study is the immediate postoperative period after
pituitary surgery where SIADH may occur but be transient and
diabetes insipidus requiring desmopressin may supervene. Here,
concomitant treatment with active therapies may pose a special
risk. Randomized controlled trials of HN therapy are needed to
compare relative efficacy, risks of over rapid correction, and
overall costs, particularly for the active treatments. Given the
strong association of HN with adverse outcomes, but persisting
uncertainty about whether HN contributes to the poor
outcomes or is only a marker of severe underlying
disease,3,4,6,7,10,14 research efforts should, in addition, focus on
which patients are more likely to respond to specific therapies
and which will directly benefit from correction of HN.
MATERIALS AND METHODS
Study plan
The study design has been described previously in detail.19 Briefly,
patients with euvolemic or hypervolemic HN were enrolled from
146 US sites and patients with euvolemic HN were enrolled from 79
EU sites. We excluded patients with hypovolemic HN because this
disorder should respond readily and completely to treatment of
volume deficits, and it therefore poses no therapeutic dilemma. We
excluded patient with hypervolemic HN from the EU study centers
because tolvaptan is only approved in the EU for euvolemic patients.
Inclusion of hypervolemic patients treated with tolvaptan would
have created a regulatory burden for the sponsor. At each site, approval
was sought from the appropriate research ethics review boards as
required. After informed consent, absent a waiver, investigators
prospectively recorded patient data. To ascertain patients, some
centers systematically reviewed hospital laboratory-generated lists of
patients with HN. Others enrolled only patients referred to or
managed by the investigator personally. The study was exclusively
observational; no standardized diagnostic or treatment protocols
were imposed. Investigators simply recorded the choices made by
the physicians responsible for the patient’s hospital care.
Inclusion and exclusion criteria
To assure that HN was clinically significant, the study required an
entry [Naþ ] p130mEq/l. Patients were excluded if o18 years old,
hypovolemic, hypervolemic (EU only), using an investigational
agent or device, or if hyperglycemic enough to interfere with assess-
ment of [Naþ ] or receiving renal replacement therapy while hypo-
natremic. As indicated in Supplementary Table S3 online, euvolemia
was defined as the absence of clinical and historical evidence of
extracellular fluid volume depletion or sequestration, and the absence
of edema and ascites, or on the basis of the treating physician’s
diagnosis of SIADH. Hypervolemia was defined as excess extra-
cellular fluid volume manifesting as dependent edema or ascites.
Although not a specified exclusion criterion originally, we subse-
quently decided to exclude any patient who was receiving a thiazide
at the time the treating physician made a diagnosis of SIADH. It
would be difficult to assure that such patients were not in fact
hypovolemic,36 and diuretic use is generally considered to be an
exclusion to the proper diagnosis of SIADH.20 This decision was
made prior to data analysis. A complete listing of inclusion and
exclusion criteria, as published previously, is provided as Supple-
mentary Table S3 online.19
Data collection
Principal data collection items included the following: admitting
diagnosis; volume status; time of hospitalization; demographics
including age (in years of age, except as489 years ifX90 years old)
gender, and race; severity of the underlying condition using standard
measures; etiology for SIADH including tumor, CNS disorder, drug
induced, pulmonary disease, other specified cause, idiopathic (cause
sought but not found), or unknown; history of prior HN; and acuity
of onset of HN, if known. HN-inducing medications, HN treatment
medications, diuretics, other medications, vital signs including
blood pressure and heart rate at admission or onset of HN and
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discharge, input and output measurements, daily weights, type and
volume of intravenous fluids administered, and FR limits were also
recorded. Any isonatric fluid was considered to be NS for purposes
of analysis. Serum osmolality, [Naþ ], blood urea nitrogen, creati-
nine, and glucose values were recorded daily as available, as were
urine osmolality and [Naþ ] and the results of testing performed to
elucidate the cause of HN or to assess severity of comorbidities
including serum potassium, alkaline phosphatase, alanine amino-
transferase, aspartate aminotransferase, total protein, thyroid-
stimulating hormone, cortisol, albumin, total bilirubin, and uric
acid; adrenocorticotropic hormone, B-type natriuretic hormone,
and N-terminal pro-B-type natriuretic peptide; hematocrit, hemo-
globin, prothrombin time, and international normalized ratio; and
urine urea nitrogen. Comorbidity procedures; HN symptoms;
conditions developing during hospitalization; intensive care unit,
intermediate care unit, and emergency department stay information;
treating physician specialty and subspecialist consults for HN were
also collected. Race was classified by the investigators (US only) and
assessed to see whether race affected treatment or outcome. The
following were also collected at discharge: timing of discharge,
discharge diagnoses, disposition, discharge location, early termina-
tion reason (if applicable), and possibility of earlier discharge.
Adjudication
To assure that entry criteria were met and that duration of HN was
evaluable, data from patients who met a prespecified review threshold
were subject to review by two members of the study Steering
Committee. Discrepancies were resolved by review by the Steering
Committee co-chairmen. Prespecified criteria triggering adjudica-
tion are listed in Supplementary Table S4 online.19 Among those
who failed adjudication and were excluded were as follows: (1)
individuals stated to be euvolemic but who presented with elevated
blood urea nitrogen:creatinine ratios and/or low urine [Naþ ]s
whose HN responded to administration of NS alone coincident with
a fall in blood urea nitrogen:creatinine ratio; (2) individuals who
were stated to be euvolemic but whose admission findings included
edema or anasarca; (3) individuals with only a single [Naþ ]
o130mEq/l who did not receive an active treatment for HN, and
(4) patients with a qualifying episode of euvolemic or hypervolemic
HN who also had a separate episode of hypovolemic HN during the
same hospitalization that would have interfered with computerized
parsing of data.
Statistical methods
Therapy periods are defined as the time interval during which a
patient received only the single therapy (monotherapy) or com-
bination specified. Patients could have had multiple episodes and
multiple therapies during the hospital stay. Initial therapy refers to
the first treatment given specifically for HN. Conivaptan was used
initially in only 6 patients and urea was used in only 10 but never as
initial therapy. Thus, we were unable to quantitate response to these
agents. For purposes of categorizing initial [Naþ ], mild HN was
defined as 130mEq/l X[Naþ ] 4125mEq/l, moderate HN as
125mEq/l X[Naþ ] X120mEq/l, and severe HN as 120mEq/l
4[Naþ ]. Overly rapid correction of [Naþ ] was defined as an
increase412mEq/l in any 24-h interval or 418mEq/l in any 48-h
interval.19 Rate of change of [Naþ ] was calculated as the total
increment in [Naþ ] during the period the treatment was utilized
divided by the number of treatment days. For patients who received
no treatment, the interval during which the patient was hypona-
tremic was used. The incremental [Naþ ] change during the first day
of treatment was calculated as the difference in [Naþ ] values at the
end and the beginning of the first 24±12 h window. The actual
interval for any individual patient ranged from 12 to 36 h, depend-
ing on the timing of the reported laboratory values. Patients who
lacked paired values during this interval were excluded from this
analysis. Duration of the initial course of HN therapy was
determined by subtracting the treatment day number of the first
day the initial HN therapy was used from the treatment day number
of the day the treatment ended and adding one.
Categorical variables were compared using a chi-square test. In
the case of more than two comparison groups, an overall w2-test was
conducted before performing individual pairwise w2-tests. Analysis
of correction criteria to test for treatment differences was performed
using a logistic regression model to adjust for the baseline [Naþ ]
levels. Analyses were performed separately using ‘no therapy’ and
‘fluid restriction’ as references for comparisons with the other
treatments.
Nonparametric analysis was performed for continuous variables.
When there were more than two comparison groups, a Kruskal–
Wallis test was conducted to generate an overall test for equality of
medians. Pairwise group comparisons were then carried out. For
comparisons of only two groups, medians were compared using the
Wilcoxon rank-sum test. P-values were not adjusted for multiple
comparisons. Data are reported as medians with interquartile range.
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